LY-451646
LY-451646 is a chemical compound that has been studied for its potential effects on the central nervous system, particularly in relation to its role as a modulator of the serotonin receptor subtypes. This compound is of interest in the field of neuropharmacology due to its potential therapeutic applications in treating various neurological and psychiatric disorders.
Chemical Structure and Properties[edit | edit source]
LY-451646 is classified as a selective agonist of the 5-HT2C receptor, a subtype of the serotonin receptor. The chemical structure of LY-451646 allows it to interact specifically with this receptor, influencing the release of neurotransmitters such as dopamine and norepinephrine.
Molecular Formula[edit | edit source]
The molecular formula of LY-451646 is C20H21F3N2O2.
Molecular Weight[edit | edit source]
The molecular weight of LY-451646 is approximately 378.39 g/mol.
Pharmacological Action[edit | edit source]
LY-451646 acts primarily as a selective agonist at the 5-HT2C receptor. This receptor is predominantly found in the central nervous system, including areas such as the hypothalamus, hippocampus, and amygdala. Activation of the 5-HT2C receptor by LY-451646 can lead to a decrease in appetite, making it a potential candidate for the treatment of obesity.
Mechanism of Action[edit | edit source]
The mechanism by which LY-451646 exerts its effects involves the modulation of serotonin pathways. By selectively activating the 5-HT2C receptor, LY-451646 can influence the release of other neurotransmitters, thereby affecting mood, anxiety, and appetite regulation.
Therapeutic Applications[edit | edit source]
Research into LY-451646 has suggested several potential therapeutic applications:
- Obesity: Due to its appetite-suppressing effects, LY-451646 has been investigated as a treatment for obesity.
- Depression and Anxiety: The modulation of serotonin pathways by LY-451646 may have implications for the treatment of mood disorders such as depression and anxiety.
- Substance Use Disorders: There is interest in the potential use of LY-451646 in reducing cravings and withdrawal symptoms associated with substance use disorders.
Research and Development[edit | edit source]
LY-451646 is still under investigation, and its safety and efficacy in humans have not been fully established. Clinical trials are necessary to determine its potential as a therapeutic agent.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
